Biotherapeutics

Pharmaceutical. Biopure Corp. Biotherapeutics. Genitope Corp. OXO Chemie. VaxGen... 

Niven RW (1995) Delivery of biotherapeutics by inhalation aerosol. In Bruck SD (ed.) Crit Rev Ther Drug Carrier Syst. Begell House Inc, New York, pp 151-231. 

BOX 3.4. ANTIBODIES AND DERIVATIVES USED AS BIOTHERAPEUTIC AGENTS AND THEIR SPECIFIC TARGETS... 

James D. McChesney NaPro BioTherapeutics, Inc., Boulder, Colorado... 

Biotherapeutic Approaches to Asthma, edited by J. Agosti and A. L. Sheffer... 

We would like to thank Drs. Robert Engle, Jean Karle, Dennis Kyle, Wil Milhous and Robert Miller of the Walter Reed Army Institute of Research for their advice and collaborations in preceding years, members of the Medicinal Chemistry Department (University of Mississippi), and Dr. James D. McChesney (NaPro Biotherapeutics). Support of this work was funded by the Department of Defense USAAMRDC (WRAIR), UNDPAVorld Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), NIAID, and the University of Mississippi Research Institute of Pharmaceutical Sciences. 

Richard F. Wintle Ellipsis Biotherapeutics Corporation, Toronto, Ontario, Canada... 

Compilation of this chapter was made possible by funding from the Crohn s and Colitis Foundation of Canada, Canadian Institutes of Health Research, Ellipsis Biotherapeutics Corporation and Genome Canada. K.A.S. is a Canadian Institutes of Health Research Senior Scientist and a McLaughlin Centre for Molecular Medicine Scientist. 

The glycoprotein interferon-p-la (IFN-p-la), an essential biotherapeutic for the treatment of multiple sclerosis, was synthesized by Kajihara and coworkers (Scheme 11.17) [88], IFN-p-la consists of 166 amino acids and has one N-glycosylation site. IFN-p-la... 

The new biotherapeutics may be defined as the molecules being discovered and studied through the disciplines of biotechnology and molecular biology. Research is currently concentrated in two main areas ... 

These new biotherapeutics are discussed briefly below, with particular reference to the problems associated with their successful dmg delivery and targeting. 

In common with the peptide and protein-based new biotherapeutics described above, successful delivery is one of the major practical problems in gene therapy. To be effective, the genetic material must ... 

Limitations of conventional drag delivery systems are particularly acute for the new biotherapeutics, such as peptide and protein drugs and nucleic acid therapies. 

List the drag delivery challenges presented by the new biotherapeutics . 

New technologies are also addressing the pulmonary delivery of the new biotherapeutics , i.e. the products of biotechnology and molecular biology such as peptides, proteins and gene therapies which have been described in detail in Chapter 1 (Section 1.6). Biopharmaceuticals under investigation for potential pulmonary delivery include those for local, and systemic, effects (Table 10.4). 

Niven, R.W. (1995) Delivery of Biotherapeutics by Inhalational Aerosol Crit. Rev. in Therapeut. Drug Carrier Sys., 12 151-231. 

Ideally, drags used in the treatment of diseases affecting the CNS would be delivered directly to the site of action. However, drags generally do not readily enter the brain from the circulating blood. Access to the brain is particularly difficult for the new biotherapeutics such as peptide, protein and nucleic-acid based biopharmaceuticals. 

---